Literature DB >> 12216100

Pretreatment cognitive performance predicts survival in patients with leptomeningeal disease.

Audrey M Sherman1, Kurt Jaeckle, Christina A Meyers.   

Abstract

BACKGROUND: Leptomeningeal disease (LMD) involves the spread of malignant cells from solid tumors to the cerebrospinal fluid or to the leptomeninges. LMD has a very poor prognosis and it is difficult to diagnose and follow with traditional diagnostic tools. The purposes of this study were to characterize cognitive functioning of LMD patients before treatment and to determine if measurement of cognitive functioning could be used to predict survival time.
METHODS: Thirty-seven subjects with LMD were administered the Mattis Dementia Rating Scale (DRS) before they received treatment and statistical analyses were performed.
RESULTS: The Conceptualization subtest of the DRS was the most sensitive to disease course. It was the only individual subtest to predict survival and it was the most impaired subtest across individual subjects. These results support earlier findings of a frontal-subcortical pattern of dysfunction in LMD patients. Cognitive performance at time of LMD diagnosis predicts survival time. Age and clinical status, two factors often correlated with survival in the cancer literature, did not predict survival time for our LMD population. In addition, there were no correlations between survival time and previous medical history or demographic factors.
CONCLUSIONS: Neuropsychological assessment appears to be a valuable tool both for tracking disease course over time and for predicting survival of patients. Copyright 2002 American Cancer Society.

Entities:  

Mesh:

Year:  2002        PMID: 12216100     DOI: 10.1002/cncr.10816

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

1.  In reference to lamborn et Al. (Neuro-oncology. 2008;10:162-170).

Authors:  Christina A Meyers; Kathleen R Lamborn; Michael D Prados
Journal:  Neuro Oncol       Date:  2008-08-25       Impact factor: 12.300

2.  Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD).

Authors:  Sherise D Ferguson; Shivani Bindal; Roland L Bassett; Lauren E Haydu; Ian E McCutcheon; Amy B Heimberger; Jing Li; Barbara J O'Brien; Nandita Guha-Thakurta; Michael T Tetzlaff; Hussein Tawbi; Michael A Davies; Isabella C Glitza
Journal:  J Neurooncol       Date:  2019-03-07       Impact factor: 4.130

3.  Neoplastic meningitis-related encephalopathy.

Authors:  Marc C Chamberlain; Denice Tsao-Wei; Susan Groshen
Journal:  J Neurooncol       Date:  2005-04       Impact factor: 4.130

4.  Prospective comparison of the prognostic utility of the Mini Mental State Examination and the Montreal Cognitive Assessment in patients with brain metastases.

Authors:  Robert Olson; Scott Tyldesley; Hannah Carolan; Maureen Parkinson; Taruna Chhanabhai; Michael McKenzie
Journal:  Support Care Cancer       Date:  2010-10-19       Impact factor: 3.603

5.  Prospective comparison of two cognitive screening tests: diagnostic accuracy and correlation with community integration and quality of life.

Authors:  Robert A Olson; Grant L Iverson; Hannah Carolan; Maureen Parkinson; Brian L Brooks; Michael McKenzie
Journal:  J Neurooncol       Date:  2011-04-26       Impact factor: 4.130

6.  Feasibility study of the Montreal Cognitive Assessment (MoCA) in patients with brain metastases.

Authors:  Robert Anton Olson; Taruna Chhanabhai; Michael McKenzie
Journal:  Support Care Cancer       Date:  2008-03-12       Impact factor: 3.603

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.